Prostate Cancer – Landscape & Forecast – Disease Landscape & Forecast

Hormonal agents dominate the treatment landscape for prostate cancer and are routinely used in all lines of therapy. Next-generation hormonal treatment has expanded beyond metastatic castrate-resistant prostate cancer (mCRPC), impacting current treatment of nonmetastatic CRPC and metastatic hormone-sensitive prostate cancer (HSPC). Continued development of the hormonal therapies, plus the development of targeted agents (e.g., Janssen / GlaxoSmithKline’s Zejula, Pfizer’s Talzenna), antibody-drug conjugates (MacroGenics’ vobramitamab duocarmazine), and novel prostate-specific membrane antigen (PSMA)-targeted radioligands (e.g., Novartis’s Pluvicto and POINT Biopharma’s 177Lu-PNT2002) will drive robust market growth over the 2022-2032 forecast period.

QUESTIONS ANSWERED

  • What are the sizes of the clinically and commercially relevant drug-treatable prostate cancer populations, and how will drug-treatment rates change over time?
  • What are the key drivers and constraints in the prostate cancer market, and how will the major markets evolve over the 10-year forecast period?
  • What is the current state of treatment for prostate cancer? What are interviewed experts’ insights on these treatment options?
  • What is the clinical and commercial potential of late-phase pipeline products, and what will be their likely positioning and uptake in the market?

PRODUCT DESCRIPTION

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

SOLUTION ENHANCEMENT

Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.

Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Table of contents

  • Prostate Cancer - Landscape & Forecast - Disease Landscape & Forecast
    • Key Findings
      • Prostate Cancer Key Findings
    • Key Updates
      • November 2023
      • July 2023
      • April 2023
      • January 2023
      • Q4 2022
        • December 2022
        • October 2022
    • Market Outlook
      • Key findings
        • Major-market share of prostate cancer drug classes: 2022
        • Major-market share of prostate cancer drug classes: 2032
        • Drug-treatable population share and major-market sales share: 2022
        • Drug-treatable population share and major-market sales share: 2032
        • Population positioning of therapies in prostate cancer
        • Prostate cancer SWOT analysis
      • Market drivers and constraints
        • What factors are driving the market for prostate cancer?
        • What factors are constraining the market for prostate cancer?
      • Segment-specific trends
        • Patient-share dynamics of key agents for newly diagnosed high-risk and N1M0 hormone-sensitive prostate cancer in the United States: 2022-2032
        • Patient-share dynamics of key agents for biochemically recurrent hormone-sensitive prostate cancer in the United States: 2022-2032
        • Patient-share dynamics of key agents for metastatic hormone-sensitive prostate cancer in the United States: 2022-2032
        • Patient-share dynamics of key therapies in nonmetastatic castrate-resistant prostate cancer in the United States: 2022-2032
        • Patient-share dynamics of key therapies in first-line metastatic castrate-resistant prostate cancer in the United States: 2022-2032
        • Patient-share dynamics of key therapies in second-line metastatic castrate-resistant prostate cancer in the United States: 2022-2032
        • Patient-share dynamics of key therapies in third- and fourth-line metastatic castrate-resistant prostate cancer in the United States: 2022-2032
    • Forecast
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Disease overview
        • Disease pathophysiology
          • Biology and metastatic spread of prostate cancer
          • Development of castrate-resistant prostate cancer
          • Molecular alterations involved in castrate-resistant prostate cancer
          • Prostate-specific antigen
          • Key clinical uses of prostate-specific antigen as a biomarker in prostate cancer
          • Staging classification and grading systems for prostate cancer
          • TNM staging classification system for prostate cancer
          • Classification of level of risk of recurrence of prostate cancer
        • Key pathways and drug targets
          • Androgen receptor-signaling pathway
          • Androgen-mediated growth of normal and cancerous prostate cells
          • PARP inhibition
          • PARP inhibition: mechanism of action
        • Anatomic location and architecture of the prostate gland
      • Epidemiology
        • Key findings
          • Key updates
        • Epidemiology populations
          • Disease definition, methods, and sources used
          • Diagnosed incident cases of prostate cancer: 2022-2032
          • Disease definition, methods, and sources used
          • Diagnosed incident cases of prostate cancer by TNM stage and NCCN risk category: 2022-2032
          • Disease definition, methods, and sources used
          • Biochemically and metastatic recurrent incident cases of prostate cancer: 2022-2032
          • Sources used for drug-treatable prostate cancer population
          • Drug-treatable cases of prostate cancer in the major pharmaceutical markets: 2022-2032
          • Prostate cancer patient-flow model
          • Sources used for prostate cancer drug-treated population
          • Drug-treated cases of prostate cancer in the major pharmaceutical markets: 2022-2032
      • Current Treatment
        • Key findings
          • Treatment goals
            • Key endpoints used in clinical trials for prostate cancer
          • Key current therapies
            • Overview
            • Mechanism of action of key current drug classes used for prostate cancer
            • Current treatments used for prostate cancer
            • Market events impacting the use of key current therapies for prostate cancer
            • Key results from clinical trials investigating abiraterone for the treatment of prostate cancer
            • Expert insight: Abiraterone
            • Key results from clinical trials investigating Xtandi for the treatment of prostate cancer
            • Ongoing clinical development of Xtandi
            • Key ongoing clinical trials of Xtandi in the treatment of prostate cancer
            • Expert insight: Xtandi
            • Key results from select clinical trials investigating Erleada for the treatment of prostate cancer
            • Ongoing clinical development of Erleada
            • Key ongoing clinical trials of Erleada in the treatment of prostate cancer
            • Expert insight: Erleada
            • Key results from select clinical trials investigating Nubeqa for the treatment of prostate cancer
            • Ongoing clinical development of Nubeqa
            • Key ongoing clinical trials of Nubeqa in the treatment of prostate cancer
            • Expert insight: Nubeqa
            • Key results from select clinical trials investigating Yonsa for the treatment of prostate cancer
            • Expert insight: Yonsa
            • Expert insight: LHRH agonist / antagonist
            • Key results from select clinical trials investigating Orgovyx for the treatment of prostate cancer
            • Expert insight: Orgovyx
            • Key results from select clinical trials investigating Pluvicto for the treatment of prostate cancer
            • Ongoing clinical development of Pluvicto
            • Key ongoing clinical trials of Pluvicto in the treatment of prostate cancer
            • Expert insight: Pluvicto
            • Key results from clinical trials investigating Provenge for the treatment of prostate cancer
            • Expert insight: Provenge
            • Key results from clinical trials investigating Xofigo for the treatment of prostate cancer
            • Ongoing clinical development of Xofigo
            • Key ongoing clinical trials of Xofigo in the treatment of prostate cancer
            • Expert insight: Xofigo
            • Key results from clinical trials investigating Jevtana for the treatment of prostate cancer
            • Expert insight: Jevtana
            • Key results from clinical trials investigating docetaxel for the treatment of prostate cancer
            • Expert insight: Docetaxel
            • Key results from select clinical trials investigating Lynparza for the treatment of prostate cancer
            • Expert insight: Lynparza
            • Key results from clinical trials investigating Rubraca for the treatment of prostate cancer
            • Ongoing clinical development of Rubraca
            • Key ongoing clinical trials of Rubraca in the treatment of prostate cancer
            • Expert insight: Rubraca
            • Key results from clinical trials investigating Talzenna for the treatment of prostate cancer
            • Ongoing clinical development program of Talzenna
            • Key ongoing clinical trials of Talzenna in the treatment of prostate cancer
            • Expert insight: Talzenna
            • Key results from clinical trials investigating Akeega for the treatment of prostate cancer
            • Analysis of clinical development program for Akeega
            • Key ongoing clinical trials of Akeega in the treatment of prostate cancer
            • Expert insight: Akeega
          • Medical practice
            • Newly diagnosed low- and intermediate-risk hormone-sensitive prostate cancer
            • Newly diagnosed high-risk and N1M0 hormone-sensitive prostate cancer
            • Metastatic hormone-sensitive prostate cancer
            • Biochemically recurrent prostate cancer
            • Nonmetastatic castrate-resistant prostate cancer
            • First-line metastatic castrate-resistant prostate cancer
            • Second- and subsequent-line metastatic castrate-resistant prostate cancer
            • Patient characteristics influencing drug selection in prostate cancer
            • Treatment decision tree for low- and intermediate-risk prostate cancer: major markets
            • Treatment decision tree for high-risk and N1M0 prostate cancer: major markets
            • Treatment decision tree for nonmetastatic castrate-resistant prostate cancer: United States
            • Treatment decision tree for metastatic hormone-sensitive prostate cancer: United States
            • Treatment decision tree for metastatic castrate-resistant prostate cancer: major markets
        • Unmet Need Overview
          • Current and future attainment of unmet needs in prostate cancer
          • Top unmet needs in prostate cancer: current and future attainment
          • Expert insight: unmet need in prostate cancer
        • Drug Pipeline
          • Pipeline
          • Regulatory Milestones
          • Indication Comparison
        • Emerging Therapies
          • Key findings
            • Key emerging therapies
              • Key therapies in development for prostate cancer
              • Estimated market authorization dates of key emerging therapies for the treatment of prostate cancer
              • Key results from select clinical trials investigating CAN-2409 for the treatment of prostate cancer
              • Analysis of clinical development program for CAN-2409
              • Key ongoing clinical trials of CAN-2409 in the treatment of prostate cancer
              • Expert insight: CAN-2409
              • Expectations for market authorization and sales opportunity of CAN-2409 in prostate cancer
              • Key results from select clinical trials investigating capivasertib for the treatment of prostate cancer
              • Analysis of clinical development program for capivasertib
              • Key ongoing clinical trials of capivasertib in the treatment of prostate cancer
              • Expert insight: capivasertib
              • Expectation for market authorization and sales opportunity of capivasertib in prostate cancer
              • Key results from select clinical trials investigating 177Lu-DOTA-rosopatamab for the treatment of prostate cancer
              • Analysis of the clinical development program for 177Lu-DOTA-rosopatamab
              • Key ongoing clinical trials of 177Lu-DOTA-rosopatamab in the treatment of prostate cancer
              • Expectations for market authorization and sales opportunity of 177Lu-DOTA-rosopatamab in prostate cancer
              • Key results from select clinical trials investigating 177Lu-PNT2002 for the treatment of prostate cancer
              • Analysis of the clinical development program for 177Lu-PNT2002
              • Key ongoing clinical trials of 177Lu-PNT2002 in the treatment of prostate cancer
              • Expectations for market authorization and sales opportunity of 177Lu-PNT2002 in prostate cancer
              • Analysis of the clinical development program for 177Lu-PSMA-I&T
              • Key ongoing clinical trials of 177Lu-PSMA-I&T in the treatment of prostate cancer
              • Expectations for market authorization and sales opportunity of 177Lu-PSMA-I&T in prostate cancer
              • Expert insight: PSMA-targeted radioligands
              • Key results from select clinical trials investigating Cabometyx in combination with Tecentriq for the treatment of prostate cancer
              • Analysis of clinical development program for Cabometyx in combination with Tecentriq
              • Key ongoing clinical trials of Cabometyx in combination with Tecentriq in the treatment of prostate cancer
              • Expert insight: Cabometyx in combination with Tecentriq
              • Expectations for market authorization and sales opportunity of Cabometyx in combination with Tecentriq in prostate cancer
              • Key results from select clinical trials investigating Verzenio / Verzenios for the treatment of prostate cancer
              • Analysis of the clinical development program for Verzenio / Verzenios
              • Key ongoing clinical trials of Verzenio / Verzenios in the treatment of prostate cancer
              • Expert insight: Verzenio / Verzenios
              • Expectations for market authorization and sales opportunity of Verzenio / Verzenios in prostate cancer
              • Key results from clinical trials investigating vobramitamab duocarmazine for the treatment of prostate cancer
              • Analysis of the clinical development program for vobramitamab duocarmazine
              • Key ongoing clinical trials of vobramitamab duocarmazine in the treatment of prostate cancer
              • Expert insight: Vobramitamab duocarmazine
              • Expectations for market authorization and sales opportunity of vobramitamab duocarmazine in prostate cancer
              • Analysis of the clinical development program for fuzuloparib
              • Key ongoing clinical trials of fuzuloparib in the treatment of prostate cancer
              • Expectations for market authorization and sales opportunity of fuzuloparib for prostate cancer
              • Key ongoing clinical trials of deutenzalutamide in the treatment of prostate cancer
              • Analysis of the clinical development program for deutenzalutamide
              • Expectations for market authorization and sales opportunity of deutenzalutamide for prostate cancer
            • Early-phase pipeline analysis
              • Select compounds in early-phase development for prostate cancer
          • Access and reimbursement overview
            • Region-specific reimbursement practices
              • Key market access considerations in prostate cancer: United States
              • General reimbursement environment: United States
              • Key market access considerations in prostate cancer: EU5
              • General reimbursement environment: EU5
              • Key market access considerations in prostate cancer: Japan
              • General reimbursement environment: Japan
          • Appendix
            • Abbreviations
            • Prostate cancer bibliography

        Login to access report